When to get anxious about social anxiety disorder

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Currently, Vimkunya is FDA-approved for use among individuals aged 12 years and older.

Michael O. Daines, MD, outlines key diagnostic criteria and treatment challenges for pediatric acute-onset neuropsychiatric syndrome (PANS), emphasizing the need for multidisciplinary care and improved treatment access.

Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.